Baird Reiterates Neutral Rating on Iovance Biotherapeutics, Inc. (IOVA)

Market Context

Iovance Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $13.31 with a market capitalization of $744.6M. The stock has gained 484.4% over the past 52 weeks.

Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Iovance Biotherapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Iovance Biotherapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 08, 2026	Baird	Neutral	N/A
Sep 30, 2026	Wells Fargo	Overweight	N/A
Sep 29, 2026	HC Wainwright & Co.	Buy	N/A
Sep 24, 2026	Goldman Sachs	Buy	N/A
Sep 17, 2026	Barclays	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View IOVA Stock Page